Loss of STAT5A promotes glucose metabolism and tumor growth through miRNA-23a-AKT signaling in hepatocellular carcinoma

Yabo Jiang1, Yongzhen Tao2, Xiuping Zhang3, Xubiao Wei1, Min Li2, Xuxiao He2, Bin Zhou1, Weixing Guo1, Huiyong Yin2 and Shuqun Cheng1

1 The Six Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
2 Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health (SINH), Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), Shanghai, China
3 Department of Hepatobiliary and Pancreatic Surgical Oncology, The First Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China

Keywords
AKT; glucose metabolism; hepatocellular carcinoma; miR-23a; STAT5A; tumor growth

Correspondence
H. Yin, Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health (SINH), Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), Shanghai 200031, China
E-mail: hyyin@sibs.ac.cn
S. Cheng, The Six Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Road, Shanghai 200438, China
E-mail: chengshuqun@aliyun.com

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. Here, we identified that increased miR-23a expression in HCC tissues was associated with worse survival. More importantly, we found that STAT5A was a target of miR-23a, whose levels significantly decreased in tumor tissues. Stable expression of STAT5A in Huh7 cells suppressed glucose metabolism and tumor growth. Finally, this study showed that increased miR-23a negatively regulated STAT5A, which further activated AKT signaling to enable rapid metabolism for accelerated tumor growth in HCC. Taken together, our results demonstrated that the miR-23a-STAT5A-AKT signaling pathway is critical to alter glucose metabolism in HCC and may offer new opportunities for effective therapy.

Abbreviations
GC/MS, gas chromatography/mass spectrometry; HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombus; STAT5A, Signal Transducer and Activator of Transcription 5A.
1. Introduction

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide [1] and fourth most commonly diagnosed cancers among Chinese men [2]. Although progress in understanding, diagnosing, and treating patients with HCC has been made in the past decade, the outcome of treatments remains unsatisfactory because of frequent recurrence and drug resistance [3,4]. In recent years, there has been a growing interest in understanding cancer metabolism, especially the reprogramming of glucose metabolism in cancer cells. Moreover, therapeutic potential of selectively targeting glucose metabolisms in cancer cells has been exploited [5].

MicroRNAs (miRNAs) are reported to play various roles in HCC [6]. miRNA-34a promotes tumor metastasis in HBV-positive HCC patients [7]; decreased miR-199a/b-3p in HCC suppresses HCC growth by inhibiting PAK4/Raf/MEK/ERK signaling pathway [8]. miR-23a is also aberrantly expressed in several human cancers as reported before [9–12]. miR-23a can regulate proliferation in prostate cancer cells by targeting sinomenine [13]. Besides, enhanced glutaminase and glutamine metabolism can be observed by suppression of miR-23 in PC3 cells [14]. However, a single microRNA is able to regulate multiple mRNAs according to some database (miR코RN.org, TargetScan, microRNASeq). Other potential targets and signaling of miR-23a in HCC are not clear.

Previous evidence also demonstrates that miR-23a is upregulated in HCC and suppresses gluconeogenesis through STAT3 and PGC-1α/G6PC [15]. Signal Transducer and Activator of Transcription 5 (STAT5), another member of the STAT family (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6), can be activated by many cytokines [16–18] and detected in many solid tumors [19–22]. There are two STAT5 isoforms, STAT5A and STAT5B, which are encoded by two interconnected genes on chromosome 17 [23]. Although both STAT5 isoforms are roughly 95% homologous at the level of cDNA, they present different contributions to carcinogenesis. Notably, loss of STAT5 signaling results in hepatic steatosis through elevated STAT1/STAT3 activity [24,25] and CD36 [26]. STAT5A also acts as a key tumor suppressor by reciprocally inhibiting expression of NPM1-ALK [27]. However, the precise role of STAT5A in HCC to glucose metabolism is still not clear.

In this study, we found that miR-23a expression was upregulated in HCC, while its target, STAT5A, was greatly reduced and associated with poor RFS and OS. Besides, we verified that increased STAT5A inhibited cell proliferation in vitro and in vivo and also reduced glucose consumption and lactate production. Using a metabolic flux analysis based on GC/MS platform, we demonstrated that STAT5A was important in metabolic reprogramming of glucose metabolism in vitro and in vivo. Importantly, we revealed that miR-23a-STAT5A-AKT signaling was responsible for this changed glucose metabolism in HCC and this axis may offer new chance for effective therapy

2. Materials and methods

2.1. Cell culture

The cells were purchased from the Chinese Academy of Science Cell Bank. All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS, Hyclone) and 1% penicillin-streptomycin (Gibco, New York, NY, USA), in an atmosphere of 95% air and 5% CO2.

2.2. Tissue microarray

All HCC human specimens were obtained after hepatectomy. The patients provided written informed consent before the surgery according to the rules and regulations of our institution. Immunohistochemistry was performed using the STAT5A antibody (Abcam, Cambridge, MA, USA, ab32043). Horseradish peroxidase-conjugated anti-rabbit secondary antibodies were then applied. Score of the tissue microarray was performed with aPERIO IMAGESCOPE v12.0.1.5027 (Leica Biosystems, Buffalo Grove, IL, USA).

2.3. RNA interference

2 × 10^5 cells were seeded in a 6-well plate first. After 24 h of adherent culture, siRNA/miRNA was transfected into cells by Lipofectamine 2000 Transfection Reagent (Invitrogen, Carlsbad, CA, USA) and lasted for 48 h. Then, cells were lysed using cell lysis buffer in order to perform western blot measurement. The siRNA sequences are listed as follows. siRNA-STAT5A: sense 5'-GCUGGCUAAAGCUGUUGAUUAGUGUUAUUAUUAUGGGGUAU-3', anti-sense 5'-UAUACGUUUCAGUUAUGCCGCUAUGUUAUUAUUAUGGGGUAU-3'. hsa-miRNA 23a mimics: sense 5'-AUCAUCCAGGGAUUC-3', anti-sense 5'-AAUCCUCAUCGCAAUUGUUGAUUU-3'. hsa-miRNA 23a inhibitor: 5'-GGAAAUCCUGGCAUGUAGAU-3'.
2.4. Cell proliferation and cell cycle
For the proliferation assays, cells were seeded into 96-well plates (2000 cells per well) at the same time. Cell viability was determined every 24 h using a Cell Counting Kit-8 (OBIO Cell Counting Kit, OCPA(C) 2012001, Obio Technology, Shanghai, China), according to the manufacturer’s instructions. For cell cycle analysis, both floating and adherent cells were collected and washed with cold phosphate-buffered saline (PBS) and fixed with 70% ethanol overnight at 4 °C. Cells were then treated with staining buffer (PBS containing 1 mg·mL⁻¹ PI and 10 mg·mL⁻¹ RNaseA (Beyotime, C1052, Shanghai, China) at 37 °C in the dark for 30 min. The samples were analyzed with a flow cytometer (Beckman, Quanta SC).

2.5. Cell migration assays
Using Trans-well Permeable Supports (Corning, New York, NY, USA), 1 × 10⁴ cells were suspended in DMEM (FBS-free) and plated in the top chamber. DMEM containing 10% FBS was added to the bottom chamber. After 48 h, migratory cells in the bottom chamber were stained by crystal violet, and cell number was pictured (Olympus TH4-200, Tokyo, Japan) and counted by Adobe Photoshop CS4.

2.6. Western blot
Cells were lysed in ice-cold lysis buffer and EDTA-free protease inhibitors (Biotool, Switzerland). In western blotting experiments, proteins were separated on 10% SDS/polyacrylamide gels, and transferred to poly (vinylidene fluoride) (PVDF, Millipore, Burlington, MA, USA) membranes. Antibodies included STAT5A (Abcam, ab32043), and STAT5A phospho Y694 (Abcam, ab30648), p-AKT (S473) (CST, 4060S, Danvers, MA, USA), p-AKT (T308) (CST, 13038S), GAPDH (ProteinTech, 60004-1-Ig), and AKT (ProteinTech, 10176-2-AP).

2.7. Luciferase activity
Huh7 cells were seeded into 48-well plates and were cotransfected with a mixture of 200 ng of firefly luciferase reporter, 10 ng of pRL-CMV Renilla luciferase reporter, and miR-23a mimics or inhibitor (20 nm). After 48 h, the firefly and Renilla luciferase activities were measured with a dual-luciferase reporter assay (Promega, Madison, WI, USA).

2.8. RNA fluorescence in situ hybridization (FISH)
The detailed steps of FISH were carried out as reported [28]. Oligonucleotide modified probe sequence for human miRNA 23a. The analysis software Image-Pro plus 6.0 (Media Cybernetics, Inc, Rockville, MD, USA) was applied to acquire the Immunofluorescence Accumulation Optical Density (IOD) for evaluating the expression of miRNA 23a in HCC tissues.

2.9. Immunohistochemistry
IHC was performed according to the previous report [29]. According to the intensity of staining (0: no staining, 1: weak staining, 2: moderate staining, and 3: strong staining) and the percentage of stained cells (0: 0%, 1: 1–24%, 2: 25–49%, 3: 50–74%, and 4: 75–100%), each specimen was assigned a final score determined by multiplying the intensity score with the percentage score (scored as 0, 1, 2, 3, 4, 6, 8, 9, and 12). Antibodies included STAT5A (Abcam, ab32043), p-AKT (S473) (CST, 4060S), and p-AKT (T308) (CST, 13038S).

2.10. Glucose consumption and lactate production
2 × 10⁶ cells were seeded in a plate first. After 24 h of adherent culture, the amounts of glucose and lactate present in the medium were tested by the D-Glucose Enzymatic Bio-Analysis Kit from R-Biopharm (Cat.No.10716251035) and the L-Lactic acid Enzymatic Bio-Analysis Kit from R-Biopharm (Cat.No.10139084035), respectively.

2.11. Metabolic flux experiments using [U-¹³C₆]-glucose
The medium used for uniformly labeled [U-¹³C₆]-glucose experiments consisted of low-glucose DMEM (Gibco 11054-020: 1 g·L⁻¹ glucose, no glutamine) with supplement of 1 g·L⁻¹ [U-¹³C₆] glucose, 10% (v/v) fetal bovine serum, the 1 mM pyruvate, the unlabeled 2 mM L-glutamine, and 1% (v/v) penicillin–streptomycin (Gibco). The medium was adjusted to pH 7.0–7.4 and filtered sterilization for usage. Cells were seeded at a density of approximately 2 × 106 cells per 10 cm dish. Labeling medium was used to replace the unlabeled medium when cells grew up to ~ 60% confluence. At this point, it was regarded as t = 0 h. Cell samples at 12 or 24 h were collected. In brief, we
collected cell samples and extracted metabolites as follows: We quickly aspirated the medium completely and immediately, put plates on dry ice, and added 2 mL of 50% (vol/vol) methanol (cooled to −80 °C) to incubate for 20 min on dry ice. Next, we scraped the plates on the dry ice with cell scraper and transferred the cell lysate/methanol mixture to a 5-mL tube on dry ice, and centrifuged the tube at 14 000 g for 5 min at 4−8 °C, and again transferred the metabolite-containing supernatant to a new 5-mL tube on dry ice. After adding 500 µL 50% (vol/vol) methanol to the pellet in 5-mL tubes and vortexed for 1 min at 4−8 °C, we spun the tubes at 14 000 g for 5 min at 4−8 °C, and then transferred the supernatant to the above 5-mL supernatant tube together, and mixed and divided 90% of total extractions to new 1.5-mL tubes for metabolite measurement. About 10% of total volume was transferred to another new tube for protein concentration determination for normalization. Finally, we used speed Vac to lyophilize to a 1.5 mL pellet using no heat and stored them at −80 °C for analysis.

2.12. Labeled metabolites of isotopomer measurement by GC/MS

Nonsugar metabolites were derivatized for GC/MS analysis and followed a previously published protocol [30]. First, 70 µL of 20 mg·mL−1 O-isobutylhydroxylamine hydrochloride (TCI) was added to the dried pellet and incubated for 20 min at 80 °C. After cooling, 30 µL N-tert-butyl(dimethyl)silyl-N-methyltrifluoroacetamide (Sigma, Darmstadt, Germany) derivatizing agent was added and samples were reincubated for 60 min at 80 °C before centrifugation for 10 min at 18 000 g (4 °C). The supernatant was transferred to an autosampler vial for GC/MS analysis. A Shimadzu QP-2010 Ultra GC/MS was programmed with an injection temperature of 250 °C injection split ratio 1/10 (depending upon sample concentration) and injected with 1 µL of sample. GC oven temperature started at 110 °C for 4 min, rising to 230 °C at 3 °C·min−1 and to 280 °C at 20 °C·min−1 with a final hold at this temperature for 2 min. GC flow rate with helium carrier gas was 50 cm·s−1. The GC column used was a 30 m × 0.25 mm × 0.25 mm HP-5ms. GC/MS interface temperature was 300 °C, and (electron impact) ion source temperature was set at 200 °C, with 70 V/150 µA ionization voltage/current. The mass spectrometer was set to scan m/z range 50−800, with 1 kV detector. GC/MS data were analyzed to determine isotope labeling and quantities of metabolites. Metabolites with baseline separated peaks were quantified on the basis of total ion count peak area, using standard curves generated from running standards in the same batch of samples. To determine 13C labeling, the mass distribution for known fragments of metabolites was extracted from the appropriate chromatographic peak. These fragments either contained the whole carbon skeleton of the metabolite, or lacked the alpha carboxyl carbon, or (for some amino acids) contained only the backbone minus the side chain [31]. For each fragment, the retrieved data comprised mass intensities for the lightest isotopomer (without any heavy isotopes, M0) and isotopomers with increasing unit mass (up to M6) relative to M0. These mass distributions were normalized by dividing by the sum of M0 to M6 and corrected for the natural abundance of heavy isotopes of the elements H, N, O, Si, and C, using matrix-based probabilistic methods as described [32], and implemented in MATLAB [33]. Labeling results are expressed as average fraction the particular compound that contains isotopic label from the particular precursor.

2.13. Animals

Xenografts derived from Huh7 were subcutaneously implanted in 4-week-old male nude mice and were randomly separated into groups. Tumor volume was estimated using the formula 0.52*length*width². All procedures were in agreement with the guidelines for the Care and Use of Laboratory Animals and were approved by the Animal Care and Use Committee, Shanghai Institutes for Biological Sciences.

2.14. Statistics analysis

Statistical analyses were performed with sss version 21.0 software (IBM, New York, NY, USA). Other experiments of significant differences between groups were determined using the Student’s t test (two-tailed) by graphpad prism 8.0 software (San Diego, CA, USA). The investigators were totally blinded to group allocation during data collection and analysis.*P < 0.05, **P < 0.01, ***P < 0.001.

All other materials and methods are described in the supplementary information.

3. Results

3.1. miR-23a is highly expressed and associated with poor survival in HCC patients

To evaluate the potential of miR-23a as a prognostic indicator, we first checked the expression of miR-23a
in HCC tissues by fluorescence in situ hybridization (FISH). Results demonstrated that miR-23a importantly increased in human tumor tissues (Fig. 1A). As listed in Table S1, high miRNA 23a expression was associated with high total bilirubin (TB) level and high portal vein tumor thrombus (PVTT) occurrence rate. The Kaplan–Meier survival test was then performed. It was shown that high levels of miR-23a were associated with poor overall survival (OS) \( (P < 0.001) \) and disease-free survival (DFS) \( (P = 0.002) \) rates (Fig. 1B, C). Multivariate analyses further revealed that increased miR-23a expression, together with encapsulation, big tumor size, and high AFP level, was independent risk factors for OS and DFS (Fig. 1D,E). To address the functional role of enhanced miR-23a in HCC growth, miR-23a mimic and miR-23a inhibitor were transfected into Huh7 cells first for 48 h (Fig. 1F). Xenograft mouse model verified that increased miR-23a could promote tumor growth (Fig. 1G,H), while inhibition of miR-23a inhibited tumor formation. Taken together, these data revealed that miR-23a was associated with patients’ survival and played oncogenic role in HCC progression.

3.2. STAT5A is a direct target of miR-23a

By searching online database library, we found numerous potential target proteins, which may have miR-23a binding sites within 3′ UTR. STAT5A was one of these candidate targets according to bioinformatic analyses (microRNA.org, TargetScan, microRNASeq). To verify this hypothesis, STAT5A 3′ UTR, containing miR-23a binding site or mutated miR-23a binding site, was cloned downstream of the luciferase open reading frame (Fig. 2A). The luciferase constructs were transfected into Huh7 cells with miR-23a mimic or miR-23a inhibitor, respectively. Altered expression of luciferase activity was observed in the STAT5A group, but not in STAT5A mutant 3′ UTR groups (Fig. 2B). Using qRT-PCR and western blotting analyses, we also confirmed that miR-23a controlled the expression of STAT5A negatively (Fig. 2C,D). We then studied the biological functions of STAT5A in Huh7 cells. Growth curves demonstrated that overexpressed STAT5A could inhibit cell proliferation and STAT5A knockdown could increase cell proliferation \textit{in vitro} (Fig. 2E). Consistently, flow cytometry results suggested that the percentage of cells in G0/G1 phase significantly increased in the high STAT5A group compared with the control group, while percentages in the G2/M phase decreased (Fig. S1A–D). Additionally, increased STAT5A also suppressed cell migration (Fig. 2F,G).

3.3. Loss of STAT5A contributes to poor prognosis in HCC patients

Considering the role of STAT5A in HCC is controversial, we first checked the protein level of STAT5A in paired nontumor adjacent tissues (N) and tumors tissues (T) by IHC staining including 148 HCC specimens (Fig. 3A). Other clinicopathological characteristics are shown in Table S2. According to the scores evaluated by the staining-positive cells, we found that STAT5A expression was sharply reduced in tumor tissues compared with nontumor adjacent tissues. This decline was also found in patients’ plasma (Fig. 3B). Besides, as shown in the Kaplan–Meier survival curves, patients with high expression of STAT5A received a much better OS \( (P = 0.016) \) and DFS \( (P = 0.014) \) (Fig. 3C,D). Multivariate Cox regression analysis demonstrated that decreased STAT5A expression, together with encapsulation, big tumor size, and high AFP level, was an independent factor associated with RFS and OS (Fig. 3E,F). To determine whether the combination of miR-23a and STAT5A was a more accurate prognostic factor, patients were classified into four groups according to their miR-23a and STAT5A expression. Patients in group 4 (low STAT5A + high miR-23a) received a worst OS (Fig. 3G). Therefore, our results suggest that STAT5A was significantly downregulated in liver tumor tissues and may serve as a potential prognosis biomarker in HCC.

3.4. Overexpressed STAT5A represses glucose metabolism and tumor growth in HCC

Increasing evidences between signaling pathways and metabolic activities are reported, and the importance of metabolic reprogramming in cancers is also widely recognized. To test whether STAT5A influences glucose metabolism, we first measured glucose uptake and lactate secretion in STAT5A overexpression cells. Results confirmed that overexpressed STAT5A decreased glucose uptake and lactate product importantly (Fig. S2A,B). What’s more, to explore the detailed changes during glucose metabolism, we used stable isotope-labeled \([U-^{13}C_6]\) glucose to track metabolic flux and quantify metabolite production in cells (Fig. 4A).

We observed that the ratio of enriched labeled carbon of metabolites including lactate, pyruvate, and
Alanine from labeled [U-13C6]-glucose decreased apparently in over-STAT5A group, suggesting that overexpressed STAT5A suppressed glycolysis rate (Fig. 4B). Similarly, the fraction of labeled carbon of citrate and aspartate in TCA pathways (Fig. 4B) also clearly reduced, implicating a slowed TCA metabolism. Further quantification of cellular intermediate metabolites in glycolysis and TCA also demonstrated that overexpressed STAT5A reduced lactate, pyruvate, succinate, and citrate about 3 times (Fig. 4C), which was agreed with the labeled results that STAT5A overexpression inhibited glycolysis and TCA metabolism in...
HCC. Indeed, this weakened glucose metabolism inhibited tumor growth in vivo as we expected (Fig. 4D,E). To further confirm this founding, we use dasatinib (Selleck, S1021) as a STAT5A inhibitor (Fig. S2C). In line with these results, we implanted Huh7 cells in nude mice and then randomly separated mice into two groups. Dasatinib (Selleck, S7782) was injected intraperitoneally (50 mg·kg⁻¹) [34] when we measured tumor volume.

Fig. 2. STAT5A, target of miR-23a, influenced tumor proliferation and migration in HCC. (A) miR-23a binding sites in STAT5A 3'UTR. (B) Relative luciferase activity of STAT5A or STAT5A mutation plasmids with miR-23a mimic or inhibitor cotransfection in Huh7 cells (n = 6). (C, D) RNA and protein level of STAT5A regulated by miR-23a (n = 3). (E) Cell proliferation with or without STAT5A expression in Huh7 cells (n = 6). (F, G) Cell migrations with or without STAT5A expression in Huh7 cells (n = 3) (Scale bar, 20 μm). All results are presented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001.

Molecular Oncology 15 (2021) 710–724 © 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
every 3 days compared with PBS in the control group. A faster tumor growth was observed in nude mice treated with dasatinib (Fig. 4F–I). Thus, these data demonstrate that STAT5A can attenuate glucose metabolism and tumor growth in HCC.

3.5. Decreased STAT5A induces AKT phosphorylation and accelerates cell metabolism in HCC

Next, we set out to elaborate the mechanisms of how loss of STAT5A expression promoted glucose metabolism and tumor growth in HCC. Study demonstrates that Akt is a ‘Warburg kinase’, which is important for enhanced cellular energy metabolism and oncogenesis [35]. Surprisingly, enhanced AKT phosphorylation was observed when STAT5A was knocked down genetically (Fig. 5A), which could explain the phenotypes presented above. Notably, inhibiting only p-STAT5A expression by dasatinib, p-AKT level still increased significantly (Fig. 5B). Besides, after transfecting miR-23a into Huh7 cells, a positive regulation was also found between miR-23a and p-AKT (Fig. 5C). To further corroborate this relationship, we checked the expression of STAT5A and p-AKT in 20 HCC specimens by IHC and also revealed a same negative correlation between STAT5A and p-AKT (P = 0.0246) (Fig. 5D). Thus, our findings provide evidence that loss of STAT5A leads to AKT activation and promotes cellular metabolism and tumor growth in HCC.

3.6. Inhibiting AKT phosphorylation attenuates increased glucose metabolism and tumor growth induced by loss of STAT5A

To evaluate loss of STAT5A accelerates glucose metabolism and HCC via AKT activation, we inhibited AKT phosphorylation by MK2206 (Fig. 6A) when
STAT5A was knocked down and measured metabolic flux and tumor growth in vivo. Results demonstrated that knockdown of STAT5A expression promoted glycolysis and TCA metabolism (Fig. 6B–E), while inhibiting AKT successfully reversed this higher glucose metabolism (Fig. 6B–E). Besides, after constructing siSTAT5A cells in dishes with siRNA for 48 h, similar results were also observed that tumor growth was inhibited significantly by MK2206 compared with the STAT5A knockdown group (Fig. 6F, 70x782.4)}
Taken together, as shown in Fig. 7, in normal liver tissue, low miR-23a expression accelerates STAT5A expression, and AKT cannot be excessively activated. However, in liver tumor tissue, high expression of miR-23a contributes to a decreased expression of STAT5A. Furthermore, STAT5A subsequently induced AKT phosphorylation, which resulted in enhanced tumor glucose metabolism and tumor growth in HCC. Our research suggests that miR-23a and STAT5A may serve as potential diagnosis markers and targeting miR-23a-STAT5A-AKT signaling may offer new treatment choices for HCC patients.

4. Discussion

In this present work, we found that miR-23a was aberrantly expressed in HCC and could serve as a promising prognostic factor for patients. Meanwhile, to our knowledge, it was also the first study that revealed that STAT5A was a direct target of miR-23a. Furthermore, we confirmed that increased miR-23a promoted glucose metabolism and tumor growth through miR-23a-STAT5A-AKT signaling in HCC.

MicroRNAs (miRNAs) play important roles in HCC progression [36]. Our previous study suggested...
that the activation of the TGF-β-miR-34a-CCL22 axis could promote HCC cells disseminated into the portal venous system through the creation of an immune-subversive microenvironment [7]. Besides, another experiment revealed that increased miR-135a facilitated PVTT formation by targeting metastasis suppressor 1 (MTSS1) [37]. Here, in this study, we also found that miR-23a sharply increased and high expression of miR-23a could contribute to poor survival in HCC patients. Increased miR-23a accelerated tumor growth in vitro.
and in vivo. miR-23a has been widely reported in different cancers. c-Myc enhances mitochondrial glutaminase and glutamine metabolism by suppressing the expression of miR-23 [14]. miR-23a is also essential for CD4+ T-cell function [10]. On the other hand, miR-23a in HCC leads to decreased glucose production, which directly targets PGC-1α and G6PC [15]. Another recent article shows that miR-23a from exosomes regulates PD-L1 expression in macrophages to help HCC cells escaping from immune system [38]. As a particular miRNA has various potential targets, we first reported that STAT5A was a direct target of miR-23a.

Evidences have revealed that STAT5 is important in cell growth, cell cycle, lipid metabolism, hematopoiesis, host defense, and immunoregulation in HCC [20,27,39,40]. Due to differences in the transactivation domain, STAT5A and STAT5B, two isoforms of STAT5, exhibit various and different oncogenic functions. STAT5B deficiency can result in immunodeficiency and growth failure [41,42]. Specifically, STAT5B is important for the FOXP3 and interleukin-2Rα (CD25) [43,44], which are responsible for the differentiation of regulatory T cells. At the same time, STAT5A also contributes to cell cycle. Cdkn2b and NPM1-ALK are under the control of STAT5A [27,45]. Therefore, in this study, we first confirmed the expression of STAT5A in HCC tissues and explored the relationship between STAT5A expression and patients’ survival. Results showed that decreased expression of STAT5A resulted in poor patients’ survival. On the other hand, function roles explored in vitro and in vivo suggested that STAT5A could inhibit tumor growth and migration. The importance of metabolic reprogramming in cancers is being increasingly recognized. In many cancers, increased glucose uptake exists to support the rapid cell growth and proliferation [46]. Moreover, cancer cells also have increased glutamine uptake and glutaminolysis, which, in turn, replenish medium production of the tricarboxylic acid (TCA) cycle [47]. Compatible with previous reports that miR-23a influenced glucose metabolism in cancers, we observed that over-STAT5A could importantly restrict glucose metabolism especially the glycolysis using stable isotope-labeled [U-13C6] glucose tracking.

Mechanistically, in this study, we found that STAT5A also negatively mediated AKT phosphorylation. This result was confirmed in common liver cell lines and human tissues. Increasing evidence showed that activation of AKT contributes to enhanced glucose uptake [48], which can explain the phenotype we found. To verify the STAT5A-AKT pathway, we added AKT inhibitor into cells on the basis of siSTAT5A. Results demonstrated that we were able to reverse the phenotype induced by knockdown of STAT5A. It is reported that activated STAT5 proteins induce activation of the PI3-kinase/Akt via the Gab2 scaffolding adapter in Ba/F3 cells [49]. However, we did not find the same mechanism in HCC cell lines. What’s more, loss of STAT5 signaling led to hepatic steatosis through elevated STAT1/STAT3 activity [24,25], which was also observed in STAT5A over-/downexpression cells. Another study also revealed that IL-6 induced activation of the JAK/STAT3 pathway and also activated the PI3K/AKT and the MEK/ERK pathway [50]. Therefore, we thought that STAT5A may mediate AKT through STAT3 pathway. The exact causality between STAT5A and AKT is not fully understood, and we have established hepatic deletion of STAT5A model to further explore the role of STAT5A in HCC progression.

5. Conclusions

In summary, our study identified that miR-23a was upregulated in HCC, which further inhibited STAT5A expression and promoted tumor growth through activated AKT phosphorylation. miR-23a-STAT5A-AKT pathway may offer new chance for specially targeted and more effective therapy.
Acknowledgements
This work was supported by the Key Project of Natural Science Foundations of China (No:81730097), Shanghai Sailing Program (20YF1459700), and the Project of Natural Science Foundations of China (No:82072618).

Conflict of interest
The authors declare no conflict of interest.

Author contributions
YBJ, YZT, HYY, and SQC designed and planned the study. YBJ, YZT, XPZ, and XBW developed and optimized experimental protocols. YBJ, YZT, ML, and XXH performed experiments. BZ and WXG organized patient enrollment, sample collection, and clinical data curation. YBJ, YZT, XPZ, and XBW analyzed and interpreted data. YBJ, YZT, XPZ, XBW, ML, and XXH wrote the manuscript and incorporated feedback from all authors. HYY and SQC provided critical revisions.

Data accessibility
No datasets were generated or analyzed during the current study.

References
1 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J & Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65, 87–108.
2 Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ & He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66, 115–132.
3 Whittaker S, Marais R & Zhu AX (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29, 4989–5005.
4 Maluccio M & Covey A (2012) Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 62, 394–399.
5 Hay N (2016) Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat Rev Cancer 16, 635–649.
6 Vasuri F, Visani M, Acquaviva G, Brand T, Fiorentino M, Pession A, Tallini G, D’Errico A & de Biase D (2018) Role of microRNAs in the main molecular pathways of hepatocellular carcinoma. World J Gastroenterol 24, 2647–2660.
7 Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, Deng Y, Zhao J, Jiang S, Yuan Y et al. (2012) TGF-beta-miR-34a-CCL2 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 22, 291–303.
8 Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y et al. (2011) Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19, 232–243.
9 Frampton AE, Castellano L, Colombo T, Giovannetti E, Krell J, Jacob J, Pellegrino L, Roca-Alonso L, Funel N, Gall TM et al. (2015) Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. Lancet 385(Suppl 1), S37.
10 Zhang B, Liu SQ, Li C, Lyken E, Jiang S, Wong E, Gong Z, Tao Z, Zhu B, Wan Y et al. (2016) MicroRNA-23a curbs necrosis during early T cell activation by enforcing intracellular reactive oxygen species equilibrium. Immunity 44, 568–581.
11 Lin R, Chen L, Chen G, Hu C, Jiang S, Sevilla J, Wan Y, Sampson JH, Zhu B & Li QJ (2014) Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. J Clin Invest 124, 5352–5367.
12 Roufayel R & Kadry S (2017) Expression of miR-23a by apoptotic regulators in human cancer: a review. Cancer Biol Ther 18, 269–276.
13 Xu F, Li Q, Wang Z & Cao X (2019) Sinomenine inhibits proliferation, migration, invasion and promotes apoptosis of prostate cancer cells by regulation of miR-23a. Biomed Pharmacother 112, 108592.
14 Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KL, De Marzo AM, Van Eyk JE, Mendell JT et al. (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762–765.
15 Wang B, Hsu SH, Frankel W, Ghoshal K & Jacob ST (2012) Stat3-mediated activation of microRNA-23a suppresses glucoseogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology 56, 186–197.
16 Weiss-Messer E, Merom O, Adi A, Karry R, Bidosee M, Ber R, Kaploun A, Stein A & Barkey RJ (2004) Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Mol Cell Endocrinol 230, 109–123.
17 Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M & Sytkowski AJ (2006) Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate...
epithelial and prostate cancer cells. *Prostate* **66**, 135–145.

18 Dagvadorj A, Collins S, Jomain JB, Abdulghani J, Karras J, Zellweger T, Li H, Nurmi M, Alanen K, Mirtti T *et al.* (2007) Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. *Endocrinology* **148**, 3089–3101.

19 Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng CX, Robinson GW & Hennighausen L (2004) Inactivation of Stat5a in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. *Mol Cell Biol* **24**, 8037–8047.

20 Hosui A, Kimura A, Yamaji D, Zhu BM, Na R & Hennighausen L (2009) Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-[-beta] and STAT3 activation. *J Exp Med* **206**, 819–831.

21 Talati PG, Gu L, Ellsworth EM, Girondo MA, Trerotola M, Hoang DT, Leiby B, Dagvadorj A, McCue PA, Lallas CD *et al.* (2015) Jak2-Stat5a/b signaling induces epithelial-to-mesenchymal transition and stem-like cell properties in prostate cancer. *Am J Pathol* **185**, 2505–2522.

22 Sanchez-Ceja SG, Reyes-Maldonado E, Vazquez-Manriquez ME, Lopez-Luna JJ, Belmont A & Gutierrez-Castellanos S (2006) Differential expression of STAT5 and Bel-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma. *Lung Cancer* **54**, 163–168.

23 Buitenhuis M, Coffer PJ & Koenderman L (2004) Signal transducer and activator of transcription 5 (STAT5). *Int J Biochem Cell Biol* **36**, 2120–2124.

24 Cui Y, Hosui A, Sun R, Shen K, Gavrilova O, Chen W, Cam MC, Gao B, Robinson GW & Hennighausen L (2007) Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. *Hepatology* **46**, 504–513.

25 Barclay JL, Nelson CN, Ishikawa M, Murray LA, Kerr LM, McPhee TR, Powell EE & Waters MJ (2011) GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. *Endocrinology* **152**, 181–192.

26 Hosui A, Tatsumi T & Hikita H (2017) Signal transducer and activator of transcription 5 plays a crucial role in hepatic lipid metabolism through regulation of CD36 expression. *Hepatol Res* **47**, 813–825.

27 Zhang Q, Wang HY, Liu X & Wasik MA (2007) STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. *Nat Med* **13**, 1341–1348.

28 Zhang J, Liu H, Hou L, Wang G, Zhang R, Huang Y, Chen X & Zhu J (2017) Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression. *Mol Cancer* **16**, 151.

29 Deng YZ, Cai Z, Shi S, Jiang H, Shang YR, Ma N, Wang JJ, Guo W, Chen TW, Zong YF *et al.* (2018) Cilia loss sensitizes cells to transformation by activating the mevalonate pathway. *J Exp Med* **215**, 177–195.

30 Ma L, Tao Y, Duran A, Llado V, Galvez A, Barger JF, Castilla EA, Chen J, Yajima T, Porollo A *et al.* (2013) Control of nutrient stress-induced metabolic reprogramming by PKCzeta in tumorigenesis. *Cell* **152**, 599–611.

31 Nanchen A, Fuhrer T & Sauer U (2007) Determination of metabolic flux ratios from 13C-experiments and gas chromatography-mass spectrometry data: protocol and principles. *Methods Mol Biol* **358**, 177–197.

32 van Winden WA, Wittmann C, Heinzle E & Heijnen JJ (2002) Correcting mass isotopeomer distributions for naturally occurring isotopes. *Biotechnol Bioeng* **80**, 477–479.

33 Portnoy VA, Scott DA, Lewis NE, Tarasova Y, Osterman AL & Palsson BO (2010) Deletion of genes encoding cytochrome oxidases and quinol monoxygenase blocks the aerobic-anaerobic shift in Escherichia coli K-12 MG1655. *Appl Environ Microbiol* **76**, 6529–6540.

34 Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR & Schwepp RE (2012) Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. *Clin Cancer Res* **18**, 3580–3591.

35 Robey RB & Hay N (2009) Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. *Semin Cancer Biol* **19**, 25–31.

36 Pan JH, Zhou H, Zhao XX, Ding H, Li W, Qin L & Pan YL (2018) Role of exosomes and exosomal microRNAs in hepatocellular carcinoma: Potential in diagnosis and antitumour treatments (Review). *Int J Mol Med* **41**, 1809–1816.

37 Liu S, Guo W, Shi J, Li N, Yu X, Xue J, Fu X, Chu K, Lu C, Zhao J *et al.* (2012) MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. *J Hepatol* **56**, 389–396.

38 Liu J, Fan L, Yu H, Zhang J, He Y, Feng D, Wang F, Li X, Liu Q, Li Y *et al.* (2019) Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and up-regulate programmed death ligand 1 expression in macrophages. *Hepatology* **70**, 241–258.

39 Friedichler K, Themanns M, Mueller KM, Schlederer M, Kornfeld JW, Terracciano LM, Kozlov AV, Haindl S, Kenner L, Kolbe T *et al.* (2012) Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. *Hepatology* **55**, 941–952.
40 Mueller KM, Kornfeld JW, Friedbichler K, Blaas L, Egger G, Esterbauer H, Hasselblatt P, Schlederer M, Haindl S, Wagner KU et al. (2011) Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. *Hepatology* **54**, 1398–1409.

41 Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, Tsusbuki J, Pratt KL, Bezrodnik L, Jasper H, Tepper A et al. (2003) Growth hormone insensitivity associated with a STAT5b mutation. *N Engl J Med* **349**, 1139–1147.

42 Imada K, Bloom ET, Nakajima H, Horvath-Arcidiacono JA, Udy GB, Davey HW & Leonard WJ (1998) Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. *J Exp Med* **188**, 2067–2074.

43 Yao Z, Kanno Y, Kerenyi M, Stephens G, Durant L, Watford WT, Laurence A, Robinson GW, Shevach EM, Moriggl R et al. (2007) Nonredundant roles for Stat5a/b in directly regulating Foxp3. *Blood* **109**, 4368–4375.

44 Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, Blank RB, Meylan F, Siegel R, Hennighausen L et al. (2007) Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. *Immunity* **26**, 371–381.

45 Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, Meyuhus O, Shokat KM & Ruggero D (2010) Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. *Cancer Cell* **17**, 249–261.

46 Gatenby RA & Gillies RJ (2004) Why do cancers have high aerobic glycolysis? *Nat Rev Cancer* **4**, 891–899.

47 DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S & Thompson CB (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. *Proc Natl Acad Sci USA* **104**, 19345–19350.

48 Cairns RA, Harris IS & Mak TW (2011) Regulation of cancer cell metabolism. *Nat Rev Cancer* **11**, 85–95.

49 Nyga R, Pecquet C, Harir N, Gu H, Dhennin-Duthille I, Regnier A, Gouilleux-Gruart V, Lassoued K & Gouilleux F (2005) Activated STAT5 proteins induce activation of the PI 3-kinase/Akt and Ras/MAPK pathways via the Gab2 scaffolding adapter. *Biochem J* **390**, 359–366.

50 Zegeye MM, Lindkvist M, Falkier K, Kumawat AK, Paramel G, Grenegard M, Sirsjo A & Ljungberg LU (2018) Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells. *Cell Commun Signal* **16**, 55.

### Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig. S1.** (A–D) Cell cycle analysis with or without STAT5A expression in Huh7 cells. All results are presented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001.

**Fig. S2.** (A–B) Glucose consumption and lactate production in Huh7-Vector and Huh7-STAT5A cells (n = 3). (C) Western blot verification of STAT5A inhibition by Dasatinib. All results are presented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001.

**Table S1.** Correlations between clinicopathological characteristics and miRNA 23a expression.

**Table S2.** Correlations between clinicopathological characteristics and STAT5A expression.